XTL Biopharmaceuticals Ltd.
XTLB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $451 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $448 | $0 | $1 | $1 |
| Gross Profit | $3 | $0 | -$1 | -$1 |
| % Margin | 0.7% | – | – | – |
| R&D Expenses | $98 | $31 | $30 | $30 |
| G&A Expenses | $1,868 | $734 | $850 | $1,001 |
| SG&A Expenses | $2,046 | $734 | $850 | $1,001 |
| Sales & Mktg Exp. | $178 | $0 | $0 | $0 |
| Other Operating Expenses | $31 | $0 | $0 | $0 |
| Operating Expenses | $2,175 | $765 | $880 | $1,031 |
| Operating Income | -$2,172 | -$765 | -$880 | -$1,031 |
| % Margin | -481.6% | – | – | – |
| Other Income/Exp. Net | $1,015 | -$1,017 | -$468 | $1,466 |
| Pre-Tax Income | -$1,157 | -$1,782 | -$1,348 | $435 |
| Tax Expense | -$130 | $0 | $0 | $0 |
| Net Income | -$1,027 | -$2 | -$1,348 | $435 |
| % Margin | -227.7% | – | – | – |
| EPS | -0.15 | 0 | -0.25 | 0.08 |
| % Growth | – | 100% | -412.5% | – |
| EPS Diluted | -0.15 | 0 | -0.25 | 0.07 |
| Weighted Avg Shares Out | 6,730 | 5,450 | 5,451 | 5,320 |
| Weighted Avg Shares Out Dil | 7,042 | 5,449 | 5,449 | 6,155 |
| Supplemental Information | – | – | – | – |
| Interest Income | $34 | $41 | $36 | $8 |
| Interest Expense | $86 | $4 | $11 | $21 |
| Depreciation & Amortization | $199 | $1 | $1 | $1 |
| EBITDA | -$930 | -$764 | -$879 | -$1,030 |
| % Margin | -206.2% | – | – | – |